Dr. Sara M. Tolaney discusses key takeaways from the DESTINY-Breast09 trial that sufferers with HER2+ superior or metastatic breast most cancers ought to know.
Therapy with first-line Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) demonstrated enhancements in key survival outcomes in contrast with the usual look after these with HER2-positive superior or metastatic breast most cancers, Dr. Sara M. Tolaney emphasised in an interview with CURE, doubtlessly shifting the best way this affected person inhabitants can be handled sooner or later.
These knowledge had been garnered from the section 3 DESTINY-Breast09 trial which was introduced at the 2025 ASCO Annual Assembly.
“The mixture of [Enhertu] and Perjeta, as we noticed in DESTINY-Breast09, actually doubled progression-free survival [for patients]. Subsequently, I believe [this treatment] does current a very nice new potential first-line remedy choice for sufferers in the event that they’re newly recognized with metastatic HER2-positive optimistic breast most cancers,” Tolaney defined.
Within the interview, she delved into element on the outcomes of the DESTINY-Breast09 trial, the remedy’s security profile, and what this implies for sufferers with HER2-positive breast most cancers.
Tolaney is a senior doctor at Dana-Farber Most cancers Institute and the chief of the Division of Breast Oncology on the Susan F. Smith Middle for Ladies’s Cancers, the place she additionally serves because the affiliate director. Moreover, she is an affiliate professor of drugs at Harvard Medical Faculty, situated in Boston, Massachusetts.
CURE: What ought to sufferers with breast most cancers know concerning the DESTINY-Breast09 trial in regard to background and enrollment info?
Tolaney: Thanks. We find out about 15% to twenty% of all breast cancers are HER2-positive, and outcomes for sufferers with metastatic HER2-positive illness have dramatically advanced over the previous few years. This enchancment is essentially as a result of introduction of trastuzumab deruxtecan, also called T-DXd and Enhertu.
Enhertu is an antibody-drug conjugate that delivers chemotherapy in a focused style immediately into HER2-positive most cancers cells. It’s presently permitted as a second-line commonplace of look after sufferers with metastatic HER2-positive breast most cancers, based on knowledge from the DESTINY-Breast03 examine. This examine demonstrated unprecedented outcomes, controlling most cancers for nearly 29 months with using Enhertu.
Consequently, there’s been important curiosity in transferring Enhertu from the second-line setting to the first-line. The present first-line commonplace of care is a taxane plus Herceptin (trastuzumab) and Perjeta, or THP, which is related to a progression-free survival of a little bit beneath 19 months. The prevailing thought was that since Enhertu is performing so effectively, it could probably be a more sensible choice than our present first-line commonplace of care. Subsequently, the DESTINY-Breast09 examine was particularly designed to reply whether or not Enhertu must be the primary remedy sufferers obtain if they’ve metastatic HER2-positive breast most cancers.
What new knowledge had been shared on the DESTINY-Breast09 trial on the ASCO Annual Assembly? What do the brand new findings imply for sufferers?
The DESTINY-Breast09 examine was a randomized section 3 trial that enrolled sufferers with HER2-positive metastatic illness who had not acquired any prior systemic remedy within the metastatic setting. These sufferers had been randomized into three arms: Enhertu alone, Enhertu with Perjeta, or the usual first-line remedy of a taxane with Herceptin and Perjeta (THP). The examine was particularly designed to find out if the Enhertu arms had been superior to the present commonplace of care.
What was introduced at ASCO was knowledge from an interim evaluation evaluating Enhertu and Perjeta to THP. This comparability met the predefined standards for fulfillment on the time of the interim evaluation. In distinction, the Enhertu alone arm didn’t meet the stringent threshold set for fulfillment at this very early time level. Consequently, the Enhertu alone arm stays blinded, and sufferers proceed to be adopted. We anticipate seeing these knowledge in a future presentation.
Nevertheless, at ASCO, we introduced the comparability of Enhertu with Perjeta to THP, and located that, in essence, the mixture of Enhertu and Perjeta virtually doubled progression-free survival. This implies it allowed most cancers to be managed for almost twice so long as within the management arm. Particularly, the progression-free survival for the Enhertu and Perjeta arm was 40.7 months, in comparison with 26.9 months for THP. As you’ll be able to see, this represents a considerable distinction between the 2 arms, virtually a 14-month enchancment.
Given these very important enhancements in progression-free survival, I consider Enhertu and Perjeta might be a brand new potential first-line remedy choice for sufferers with metastatic HER2-positive breast most cancers.
How quickly would possibly this new mixture be obtainable in medical observe, and what steps ought to a affected person take if they’re occupied with discussing it with their care group?
We should await FDA approval for this routine. The info can be submitted to regulatory authorities, and we’ll then await their resolution. We additionally hope to see future adjustments within the Nationwide Complete Most cancers Community (NCCN) Pointers.
Actually, sufferers can focus on this knowledge with their physicians. Enhertu is an permitted drug, although presently for the second-line setting. So, it stays to be seen if insurance coverage suppliers would cowl Enhertu and Perjeta within the first-line setting even earlier than official approval. Generally, this occurs given how sturdy the information is, however it’s positively one thing you’ll be able to focus on along with your doctor.
What ought to sufferers know concerning the potential unintended effects of Enhertu and Perjeta, similar to nausea, fatigue, or low white blood cell counts, and the way are these managed in observe?
The toxicities noticed within the DESTINY-Breast09 examine with Enhertu and Perjeta had been largely in line with the identified unintended effects of those medicine. Widespread toxicities included nausea, diarrhea, and neutropenia.
A notable concern was interstitial lung illness (ILD), or irritation of the lungs, which developed in about 12% of sufferers within the Enhertu and Perjeta arm. Whereas predominantly low-grade inflammatory adjustments, there have been sadly two deaths attributed to ILD within the trial.
Subsequently, it is essential for sufferers receiving Enhertu and Perjeta to obtain prophylactic remedy to forestall nausea, which usually works very effectively. I normally suggest three totally different medicines to assist stop nausea with Enhertu. It is also important to watch sufferers for any adjustments of their lungs or signs that might recommend lung irritation. Sufferers ought to pay attention to ILD as a possible toxicity and will promptly inform their doctor in the event that they develop any associated signs.
The examine confirmed profit throughout subgroups. Why is that this essential for sufferers who could not reply as effectively to different therapies?
We all know that sure options of HER2-positive most cancers can generally recommend that sufferers could not reply as effectively to remedy. For instance, if a affected person has a PI3 kinase mutation, which is current in about 30% of these with HER2-positive illness, their period on a given remedy is commonly shorter than for somebody with out this mutation.
Curiously, within the DESTINY-Breast09 examine, we noticed that the advantage of Enhertu and Perjeta was seen regardless of mutational standing. This is good news. Moreover, the advantages had been additionally noticed regardless of hormone receptor standing, that means we noticed optimistic outcomes throughout all affected person subsets. This broad applicability is really essential for sufferers.
How would possibly this examine change the remedy panorama transferring ahead?
The mixture of Enhertu and Perjeta, as we noticed in DESTINY-Breast09, actually doubled progression-free survival for sufferers. Subsequently, I believe this does current a very nice new potential first-line remedy choice for sufferers in the event that they’re newly recognized with metastatic HER2-positive optimistic breast most cancers.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
